ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-10-20 19:30 |
Abivax annonce la mise à disposition d’un prospectus dans le cadre de son offre…
|
French | 876.7 KB | ||
| 2023-10-20 15:45 |
Abivax annonce la reprise des négociations de ses actions ordinaires sur Eurone…
|
French | 129.8 KB | ||
| 2023-10-20 15:45 |
Abivax announces trading resumption of its ordinary shares on Euronext Paris
|
English | 9.9 KB | ||
| 2023-10-20 15:00 |
Abivax annonce la fixation du prix de son introduction en bourse sur le Nasdaq …
|
French | 151.4 KB | ||
| 2023-10-20 15:00 |
Abivax announces the pricing of its Initial Public Offering on the Nasdaq Globa…
|
English | 26.0 KB | ||
| 2023-10-20 08:45 |
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur …
|
French | 111.2 KB | ||
| 2023-10-20 08:45 |
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
|
English | 11.4 KB | ||
| 2023-10-19 00:00 |
Abivax announces the filing of an amended registration statement, including an …
|
English | 24.1 KB | ||
| 2023-10-18 23:59 |
Abivax annonce le dépôt d’un « Amendment » au Document d’Enregistrement (« FORM…
|
French | 150.1 KB | ||
| 2023-10-16 17:40 |
Abivax annonce le début des roadshows dans le cadre de son projet d'Offre Globa…
|
French | 97.2 KB | ||
| 2023-10-16 17:40 |
Abivax announces the start of the roadshow for its proposed global offering and…
|
English | 11.8 KB | ||
| 2023-10-02 18:00 |
Abivax met en avant son programme de développement clinique d’obefazimod dans l…
|
French | 214.5 KB | ||
| 2023-10-02 18:00 |
Abivax highlights obefazimod ulcerative colitis program with new data to be pre…
|
English | 15.8 KB | ||
| 2023-09-29 23:00 |
Abivax annonce le dépôt d’un document d’enregistrement form F-1 en vue de son i…
|
French | 92.3 KB | ||
| 2023-09-29 23:00 |
Abivax files registration statement for proposed initial public offering in the…
|
English | 7.3 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
